偏頭痛治療市場：按治療方法、給藥途徑和地區分類－市場規模、佔有率、前景和機會分析（2025-2032 年）

Migraine Therapeutic Market, By Therapeutics, By Route of Administration, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

出版日期: 2026年04月01日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026年偏頭痛治療市值為75.154億美元，預計到2033年將達到143.681億美元。預計從2026年到2033年，該市場將以9.7%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	75.154億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	9.70%	2033年市場規模預測：	143.681億美元

偏頭痛是一種神經系統疾病，其特徵是頭部特定區域出現劇烈搏動性疼痛。疼痛通常為單側，常呈搏動性，且常會因體力活動而加劇。偏頭痛通常伴隨其他徵兆，例如噁心和視力障礙。目前尚無治癒偏頭痛的方法，但藥物可以預防或抑制偏頭痛發作，但也可能加重症狀。

市場動態

偏頭痛盛行率不斷上升、對安全有效治療方法的需求日益成長、公眾對偏頭痛及其治療方案的認知度提高，以及全球研發投入的活性化，預計將成為預測期內推動全球偏頭痛治療市場成長的主要因素。例如，偏頭痛是一種嚴重的常見神經系統疾病，對患者的生活品質有著深遠的影響。 2021年，世界衛生組織（WHO）將偏頭痛列為因殘疾導致健康調整生命年（DALYs）損失最大的神經系統疾病。

2022年2月，Biohaven製藥控股有限公司和輝瑞公司宣布，歐洲藥品管理局（EMA）人用藥品委員會已對瑞美吉泮（rimegepant）給予正面意見。核准75毫克劑量的瑞美吉泮（口溶錠）上市，用於治療成人伴或不伴徵兆的急性偏頭痛，以及預防每月至少發作四次的成人陣發性偏頭痛。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並為該市場說明了一個有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據公司亮點、產品系列、主要特點、財務表現和策略等參數，創建了全球偏頭痛治療市場主要公司的概況。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球偏頭痛治療市場報告的目標受群眾外包括行業內的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過分析全球偏頭痛治療市場時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 7,515.4 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	9.70%	2033 Value Projection:	USD 14,368.1 Mn

Migraine is a neurological disorder often described as intense pulsing or throbbing pain in one area of the head. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. Migraines are a type of headache that tend to cause other signs and symptoms, too, such as nausea and vision problems. There's no cure for migraines yet, but medicines can help prevent or stop them, or keep signs and symptoms from getting worse.

Market Dynamics

Increase in prevalence of migraine, increase in demand for safe and effective treatment, increase in awareness about migraine and its treatment options, and rise in research and development across the world are major factors expected to propel the growth of the global migraine therapeutic market during the forecast period. For instance, migraine is a serious and common neurological condition with a serious impact on quality of life. In 2021, migraine has been ranked by WHO as the most prevalent neurological condition causing the highest loss of years due to disability.

In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global migraine therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer Inc., Novartis International AG, Merck & Co. Inc., GlaxoSmithKline PLC, Eli Lilly and Company, AstraZeneca PLC, Amgen Inc., Allergan Inc., Bausch Health Companies Inc., and Teva Pharmaceutical Industries Ltd., among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global migraine therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global migraine therapeutic market.

Market Segmentation

Global Migraine Therapeutic Market, By Therapeutics (Revenue, USD Mn, 2021 - 2033)
Pain-relieving Medications
Preventive Medications
Global Migraine Therapeutic Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
Oral and Nasal
Injection
Global Migraine Therapeutic Market, By (Revenue, USD Mn, 2021 - 2033) Geography
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles
Pfizer Inc.
Novartis International AG
Merck & Co. Inc.
GlaxoSmithKline PLC
Eli Lilly and Company
AstraZeneca PLC
Amgen Inc.
Allergan Inc.
Bausch Health Companies Inc.
Teva Pharmaceutical Industries Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapeutics
- Market Snapshot, By Route of Administration
- Market Snapshot, By Geography
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increase in prevalence of migraine around the world
- Adverse effects of drugs and increasing undiagnosed cases
- Increase in demand for safe and effective treatment
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Migraine Therapeutic Market, By Therapeutics, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Pain-relieving Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Preventive Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

5. Global Migraine Therapeutic Market, By Route of Administration, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oral and Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

6. Global Migraine Therapeutic Market, By Geography, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Country
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Country
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Country
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Country
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Country
  - South Africa
  - North Africa
  - Central Africa

7. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis International AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co. Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Allergan Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bausch Health Companies Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views